Table 3.

5-year mortality of CCSS and SEER patients when they survived 5 years, 10 years, 15 years and 20 years after cancer diagnosis

Diagnosis Groups	CCSS	SEER
	% Death (95% CI)	% Death (95% CI)
Total Patients
5–10 years	5.96 (5.92, 6.01)	7.35 (7.22, 7.48)
10–15 years	3.03 (2.96, 3.10)	3.34 (3.12, 3.55)
15–20 years	2.47 (2.39, 2.55)	3.31 (3.08, 3.54)
20+ years	3.04 (2.97, 3.12)	5.97 (5.79, 6.15)
Leukemia
5–10 years	7.31 (7.19, 7.44)	10.96 (10.58, 11.34)
10–15 years	2.81 (2.59, 3.03)	4.55 (3.85, 5.26)
15–20 years	1.70 (1.41, 2.00)	2.01 (0.86, 3.15)
20+ years	1.67 (1.37, 1.97)	1.94 (0.71, 3.17)
Kidney tumors
5–10 years	1.70 (0.64, 2.75)	1.25 (0, 6.71)
10–15 years	0.94 (0, 2.39)	1.00 (0, 5.87)
15–20 years	1.38 (0.18, 2.58)	1.28 (0, 5.67)
20+ years	1.77 (0.69, 2.85)	1.88 (0, 5.68)
CNS
5–10 years	8.41 (8.13, 8.68)	6.40 (5.91 6.89)
10–15 years	4.89 (4.49, 5.30)	3.46 (2.72, 4.19)
15–20 years	3.82 (3.34, 4.30)	4.22 (3.53, 4.91)
20+ years	5.45 (5.03, 5.87)	8.02 (7.49, 8.54)
Lymphoma
5–10 years	4.10 (3.81, 4.39)	6.17 (5.72, 6.61)
10–15 years	2.90 (2.54, 3.26)	3.64 (3.01, 4.27)
15–20 years	3.25 (2.90, 3.60)	4.09 (3.46, 4.72)
20+ years	4.61 (4.31, 4.92)	9.38 (8.95, 9.80)
Neuroblastoma
5–10 years	2.91 (1.88, 3.94)	4.34 (1.68, 7.01)
10–15 years	1.31 (0, 2.90)	0.62 (0, 8.33)
15–20 years	0.85 (0, 2.86)	1.27 (0, 6.77)
20+ years	1.43 (0, 2.99)	1.35 (0, 6.99)
Soft tissue sarcoma/Ewing sarcoma
5–10 years	7.01 (6.63, 7.39)	7.11 (6.19, 8.02)
10–15 years	4.11 (3.57, 4.65)	2.97 (1.39, 4.55)
15–20 years	3.81 (3.23, 4.40)	3.88 (2.42, 5.34)
20+ years	3.22 (2.55, 3.89)	4.44 (3.00, 5.89)
Osteosarcoma/Other bone tumors
5–10 years	6.22 (5.44, 6.99)	7.95 (5.16, 10.74)
10–15 years	3.48 (2.36, 4.60)	4.23 (0, 8.61)
15–20 years	2.14 (0.65, 3.63)	2.94 (0, 8.46)
20+ years	3.68 (2.53, 4.84)	6.70 (2.93, 10.47)